Phoenix Molecular Designs is pleased to announce that we are now a member of the TuneLab platform from Eli Lilly and Company. TuneLab provides access to artificial intelligence (AI) and machine learning (ML)–enabled small-molecule ADMET prediction and antibody property prediction models built on decades of pharmaceutical research data.

Participation in TuneLab represents an important opportunity to further strengthen how Phoenix applies data-driven insights to advance our precision oncology pipeline and support early-stage drug discovery efforts.

We thank Vanessa Braunstein and the Lilly team for their collaboration and the opportunity to connect at Biocom’s conference.

Learn more about TuneLab:
https://tunelab.lilly.com/

Dr. Sandra Dunn spoke at the 2025 Virtual Young Women’s Health Day on the Hill, hosted by Tigerlily Foundation, where she joined fellow advocates and medical experts to champion policies that expand access to cancer treatments. She highlighted the need to advance the EPIC Act and eliminate barriers like the IRA “pill penalty,” which delay innovation in oral medicines that are more affordable, more accessible, and less burdensome on the healthcare system.

You can find the webinar recording here: https://youtu.be/W8jmfE91WbI?si=Q1hb0INAp0Rmwdg3

At PhoenixMD, we have been vocal in our support of the EPIC Act (H.R. 1492), a bipartisan effort to restore parity and protect patient access to breakthrough therapies. Earlier this year, we submitted a formal letter to U.S. representatives outlining the stakes — not just for our company, but for the future of care.

We are proud to share that letter publicly today, because standing up for patients is part of who we are.

A recent study published in Nature Communications highlights the transformative work of Stephen Oh and his team at Washington University School of Medicine in St. Louis. Their findings highlight the innovative targeting of RSK1, which offers new avenues for addressing myeloid malignancies, and reiterate the groundbreaking potential of PMD-026, developed by the team at Phoenix Molecular Designs, to transform cancer treatment and bring new hope to patients worldwide.

In the study, inhibiting RSK1 helped reverse the progression of myeloproliferative neoplasms (MPNs) in mice, significantly reducing fibrosis, or scar formation, in the bone marrow. Remarkably, inhibiting RSK1 eliminated up to 96% of cancer in mice after just four weeks, underscoring the transformative potential of this approach.

This collaboration showcases the power of innovative science and partnerships to advance precision medicine. We are proud that PMD-026 is contributing to this vital progress, bringing us closer to better outcomes for cancer patients everywhere.

Read more about this impactful research in Washington University’s news release: https://medicine.washu.edu/news/drug-in-clinical-trials-for-breast-cancer-could-also-treat-some-blood-cancers/

Dr. Sandi Dunn will attend the Pfizer Women’s Breakfast at the 43rd JP Morgan Healthcare Conference.

Dr. Sandi Dunn will attend the Pfizer Oncology Reception at the 43rd JP Morgan Healthcare Conference.

We’re proud to share that our Founder and CEO, Dr. Sandi Dunn, will be speaking at the Longwood Healthcare Leaders CEO Meeting in San Francisco on January 11 at 1:30 PM. Her session will focus on advances in clinical trials and the impact these innovations are having on patient care.

We are honored that our SABCS poster, #P4-08-27: PMD-026, a First-in-Class RSK Inhibitor, Overcomes Acquired Resistance to CDK4/6 Inhibitors or Aromatase Inhibitors in HR+/HER2- Breast Cancer Preclinical Models, has won the 2024 GRASP Advocate Choice Award.

This recognition underscores the importance of collaboration between patients, clinicians, and researchers in advancing meaningful solutions for breast cancer. Thank you to GRASP for this incredible honor!

Join us on Tuesday, December 17, during the GRASP Poster Walkthroughs, where our work will be highlighted.

Our esteemed collaborators, Kalien M. from Stanford University School of Medicine, and Tim W. from Washington University School of Medicine in St. Louis presented leading-edge studies utilizing PMD-026. Their research underscores promising data supporting the efficacy of PMD-026 in treating myeloid cancers, including Acute Myeloid Leukemia (AML).

Founder and CEO, Dr. Sandi Dunn, presented insights from Phoenix Molecular Designs’ late-breaking poster presentation. Delving into the PMD-026 Phase I/Ib study, she discussed how patient selection for high RSK2 expression could be pivotal for achieving enhanced Progression-Free Survival (PFS) in metastatic breast cancer. Find a link to the poster here: Patient Selection for High RSK2 Expression is Key for Achieving Improved PFS in Metastatic Breast Cancer in the PMD-026 Phase I/Ib Study

During Breast Cancer Awareness Month, Dr. Sandi Dunn was asked by The Province where her passion and determination to beat breast cancer comes from. Read the story here: https://theprovince.com/opinion/dr-sandi-dunn-i-lost-my-sister-in-law-to-the-most-aggressive-and-deadliest-form-of-breast-cancer

In-person celebration of the Forbes 50 Over 50 award recipients including PhoenixMD Founder and CEO, Dr. Sandra Dunn. The event will be held at the Forbes on Fifth event space in New York City for an afternoon of connection, merriment and inspiration featuring an intimate conversation with none other than the First Lady of the United States Jill Biden.

To celebrate Breast Cancer Awareness Month, we were honored to help sponsor YSC San Diego's Self Care Gathering 2021. Every October, YSC San Diego has a tradition of gathering and honoring young adults with love and pampering.

The Young Survivor Coalition (YSC) is an organization dedicated to all young breast cancer survivors and their co-survivor support network.

The first TNBC Drug Development Digital Summit begins tomorrow. Our Founder and CEO, Dr. Sandra Dunn, will be speaking on Thursday, April 29 at 8:30 am PST.

Don't miss her and other industry leaders from MD Anderson Cancer Center, Stanford University, Triple Negative Breast Cancer Foundation, Moffit Cancer Center, and Tigerlily Foundation speak about the discovery and development of TNBC treatments to reach patients in need.

Please join our CEO Dr Sandi Dunn, a guest speaker, at this important educational event for patients and supporters of women with metastatic breast cancer.

Learn more about this event here

Join the Komen's Race for the Cure®, which helps to raise important funds that are invested in ground breaking research. You can help play a critical role in furthering major advancements in breast cancer

Come and visit our booth at this event!

Details about the event in San Diego can be found here

More than 82,000 Canadians are expected to be involved in this fundraising event that is dedicated to changing the future of breast cancer.

Details about the event in Vancouver can be found here